PSMA PET, when combined with mpMRI, eventually in hybrid PET/MRI systems, provides improved sensitivity and specificity, enabling more precise tumour localization and a more personalised approach to prostate cancer management. The gene discussed is FOLH1; the disease is prostate cancer.